29/09, European Pitch Contest, Pre-Round 2, Cluster „HealthTech & Beyond“, Visionaries Stage
Key Facts
Company Description
Vivalyx is tackling the global organ shortage—a crisis that costs billions and claims millions of lives each year. Its patented technology overcomes the limits of existing solutions with a fully synthetic blood substitute. For the first time, life-saving warm perfusion—a method proven to increase organ utilization—becomes clinically scalable.
Product/Service Description
Vivalyx novel liquid Omnisol outperforms the efficacy of the blood-based benchmark in preclinical trials, is fully synthetic – eliminating blood-related concerns – and significantly cuts costs.
Website
https://vivalyx.com
Crunchbase
Country
Germany
Founding Year
2022
Employees
11-20
Company Stage
First Pilot Customers
Business Model
B2B
Focus Industries
Active Markets
(5 most relevant ones)
USA, The Netherlands, Belgium, Spain, Germany
Look for at Bits & Pretzels
Funding & Investors
3 Lead Investors
Goose Capital Houston, Brightlands Venture Partners, former CEO Novartis Pharma
Capital Raised to Date
10 000 000 €
Last Funding Type
Seed
Last Funding Date
March 2024
Capital Need (€)
5-15M
Currently Fundraising
(at the time of Bits & Pretzels 2025)
Yes
Growth Outlook
Traction
Vivalyx has generated the required data for its first production registration (expected next year).
Monetization Model
It is a consumable product sold directly to hospitals; already reimbursed under existing codes.
3 Reference Customers
BWH Boston, Erasmus MC Rotterdam, University Hospital Heidelberg